Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 2/2015

01-02-2015 | Current Opinion

Role of Apomorphine in the Treatment of Parkinson’s Disease

Authors: Allison Boyle, William Ondo

Published in: CNS Drugs | Issue 2/2015

Login to get access

Abstract

Current research shows that apomorphine is an effective treatment for symptoms of Parkinson’s Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.
Literature
1.
Hagell P, Odin P, Shing M. Apomorphine in Parkinson’s disease. UNI-MED-Verlag, 2008.
2.
Gessa GL, Corsini GU. Apomorphine and other dopaminomimetics: basic pharmacology. New York: Raven Press (ID); 1981.
3.
Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(2):85–92.CrossRefPubMed
4.
Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother Biomed Pharmacother. 1995;49(4):197–209.CrossRef
5.
6.
Ribaric S. The pharmacological properties and therapeutic use of apomorphine. Molecules. 2012;17(5):5289–309.CrossRefPubMed
7.
Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709–16.CrossRefPubMedCentralPubMed
8.
Lucotti A, Tommasini M, Casella M, Morganti A, Gramatica F, Zerbi G. TLC—surface enhanced Raman scattering of apomorphine in human plasma. Vib Spectrosc. 2012;62:286–91.CrossRef
9.
LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32(2):89–93.CrossRefPubMed
10.
Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69(2):248–56.CrossRefPubMed
11.
Gassen M, Gross A, Youdim MBH. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord. 1998;13(4):661–7.
12.
Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Clin Pharmacol. 1996;308:219–26.CrossRef
13.
Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord Off J Mov Disord Soc. 1991;6(3):212–6.CrossRef
14.
Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429–53.CrossRefPubMed
15.
Holford NG, Sheiner L. Understanding the dose–effect relationship. Clin Pharmacokinet. 1981;6(6):429–53.CrossRefPubMed
16.
Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson’s disease. Parkinsonism Relat Disord. 2000;6(4):237–40.CrossRefPubMed
17.
Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–3.PubMed
18.
Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson’s disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976;294(11):567–72.CrossRefPubMed
19.
20.
Barker R, Duncan J, Lees A. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1989;1(8639):675.CrossRefPubMed
21.
Oertel, Wolfgang H, et al. Apomorphine test for dopaminergic responsiveness. Lancet. 1989;333(8649):1262–3.
22.
Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990;336(8706):32–4.CrossRefPubMed
23.
24.
Factor SA. Literature review intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62(6 suppl 4):S12–7.CrossRefPubMed
25.
Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson’s disease. J Neurol. 1992;239(7):389–93.PubMed
26.
Bowron A. Practical considerations in the use of apomorphine injectable. Neurology. 2004;62(6 suppl 4):S32–6.CrossRefPubMed
27.
Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet. 1988;1(8582):403–6.CrossRefPubMed
28.
Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson’s disease. Lancet. 1988;1(8591):943.CrossRefPubMed
29.
Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on–off oscillations in Parkinson’s disease. Lancet. 1988;2(8622):1260.CrossRefPubMed
30.
Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease. Revue Neurol. 1990;146(2):116–22.
31.
Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96–101.CrossRefPubMedCentralPubMed
32.
Petit H, Vermersch P, Caparros-Lefebvre D. Subcutaneous apomorphine in major motor oscillations of parkinsonian patients. Presse Med. 1992;21(4):172.PubMed
33.
Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2(8626–8627):1451–3.CrossRefPubMed
34.
Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728–41.CrossRefPubMed
35.
Stacy M, Spears J, Van Lunen B. Implications of Motor fluctuations in Parkinson’s patients on Chronic Therapy (IMPACT) registry: comparison of patient and physician reported data. Mov Disord. 2006;21(Supplement 13):1.
36.
Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, et al. Sublingual apomorphine in Parkinson’s disease: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1991;14(5):432–7.CrossRefPubMed
37.
Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385–92.CrossRefPubMed
38.
Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171–6.
39.
Anthony Giovinazzo M, Dir C, CEO CT, Agro IA, Bryson N, Tankosic IT. Apomorphine for off periods in Parkinson’s disease: clinical use and potential of a developmental sublingual formulation, APL130277. In: Conference M, editor. 2013.
40.
Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100.CrossRefPubMed
41.
Isaacson S, Ondo W, Pagan F. Apomorphine improves morning akinesia in Parkinson’s disease: interim analysis of the AM-IMPAKT trial. European Journal of Neurology; 2014: Wiley-Blackwell 111 River St, Hoboken 07030–5774, NJ USA; 2014. p. 68.
42.
Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro Garcia A, Alonso Frech F, Alvarez Lopez M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord Off J Mov Disord Soc. 2008;23(8):1130–6.CrossRef
43.
Todorova A, Chaudhuri KR. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(12):1073–8.
44.
Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord Off J Mov Disord Soc. 2002;17(6):1235–41.CrossRef
45.
Manson A, Hanagasi H, Turner K, Patsalos P, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson’s disease clinical and pharmacokinetic observations. Brain J Neurol. 2001;124(2):331–40.CrossRef
46.
Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26(2):232–8.CrossRefPubMed
47.
LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl 4):S8–11.CrossRefPubMed
48.
Garrido JMPJ, Delerue-Matos C, Borges F, Macedo TRA, Oliveira-Brett AM. New insights into the oxidation pathways of apomorphine. J Chem Soc Perkin Trans 2. 2002;10:1713–7.CrossRef
49.
Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 1999;14(4):664–8.CrossRef
50.
Morgan FG, Main MJ. Compositions and uses. Google Patents; 2013.
51.
Bartus RT, Emerich DF. Pulmonary delivery in treating disorders of the central nervous system. Google Patents; 2003.
52.
Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005;76(2):181–5.CrossRefPubMedCentralPubMed
53.
Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 2010;24(4):636–41.CrossRefPubMed
54.
Pistoia F, Mura E, Govoni S, Fini M, Sarà M. Awakenings and awareness recovery in disorders of consciousness. CNS Drugs. 2010;24(8):625–38.CrossRefPubMed
Metadata
Title
Role of Apomorphine in the Treatment of Parkinson’s Disease
Authors
Allison Boyle
William Ondo
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 2/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-014-0221-z

Other articles of this Issue 2/2015

CNS Drugs 2/2015 Go to the issue

Therapy in Practice

Seizure Associated with Clozapine: Incidence, Etiology, and Management

Review Article

Taming Glutamate Excitotoxicity: Strategic Pathway Modulation for Neuroprotection

Adis Drug Evaluation

Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

Short Communication

Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study

Systematic Review

Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms

Review Article

The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research